Second, our results suggest that the HER-2(9369) peptide, besides HLA-A2, is also recognised by CTL in the context of two other alleles, namely HLA-A3 and HLA-A26, besides in breast and ovarian cancer patients and also in patients with colorectal, lung and prostate cancer. Here, ERBB2 is linked to ovarian carcinoma.